Antihypertensive Drugs Market: Adoption of Combination Therapies to Gain Significant Momentum

Rising Global Burden of Hypertension Provides Impetus for Development of New Drugs

Hypertension is a critical health condition that can lead to cardiovascular diseases, renal failure, stroke, and even death. According to the World Health Organization, 1.13 billion individuals worldwide had hypertension in 2018, of which two-third resided in low income and developing countries. Over the past decade, the global burden of hypertension has increased, primarily driven by a significant rise in population, lifestyle changes, and increase in the geriatric population worldwide. In the current scenario, hypertension is effectively controlled in less than 20% of the patients across the world, which means there is a mounting demand for antihypertensive drugs, particularly in developing regions.

Read Report Overview -

Over the past few decades, a significant amount of research has been undertaken for the discovery of new, effective, and novel antihypertensive drugs. Despite significant advancements in genomics, clinical applications of these relatively recent developments in the antihypertensive drugs market landscape remain far-fetched. Drug manufacturers continue to invest significant resources toward the discovery of blockbuster antihypertensive drugs. However, to achieve this goal, stakeholders in the current antihypertensive drugs market are likely to adopt a cross-sector approach that will focus on several areas, including data, digital, population sciences, etc.

The global antihypertensive drugs market is expected to reach a market value of ~US$ 33.9 Bn by the end of 2027.

Request Brochure of Report -

Adoption of Combination Therapies to Gain Significant Momentum

Research and development have taken the center stage in the current antihypertensive drugs market. Established and upcoming players in the current market landscape are increasingly focusing on the formulation of effective combination therapies. Uptake of combination therapies is a trend that is projected to gain significant momentum during the forecast period (2019-2027).

Focus on combination therapies in the antihypertensive drugs market is likely to increase to achieve therapeutic goals. Furthermore, recent guidelines related to hypertension management suggest that combination therapy, in which two or more drugs are combined, is ideal for patients that have systolic blood pressure and patients at a higher cardiovascular risk.

Request for Analysis of COVID-19 Impact on Antihypertensive Drugs Market -

In addition, several research activities have revealed that ~25% of patients may require a combination therapy of three antihypertensive drugs to attain the desirable outcome. Combination therapy is expected to be the most prominent medication type. The combination therapy segment of the antihypertensive drugs market is projected to reach a market value of ~ US$ 12.4 Mn and account for a market share of ~43% in 2020.

Conventionally, a higher dose of monotherapy is required. However, this approach could potentially increase the risk of side effects. These drawbacks of monotherapy have paved the way for other medication types in the global antihypertensive drugs market such as fixed dose combinations and combination therapy. With a market share of ~33%, the fixed dose combinations medication type segment is expected to hold the second-highest market share of the antihypertensive drugs market in 2020.

Request for Custom Research -

Companies Focus on R&D to Offer Effective Antihypertensive Drugs

Stakeholders in the global antihypertensive drug market are increasing their efforts toward the discovery of new drugs to manage high blood pressure. Research activities are focused on the discovery of new combination drugs. For instance, clinical trials have revealed that new combination therapy could revolutionize hypertension management worldwide.

A team of researchers from the George Institute for Global Health tested the efficacy and safety of an innovative combination drug to deal with hypertension and elevated blood pressure. The new drug, which was declared safe after a series of clinical trials, is a combination of three drugs - amlodipine, chlorthalidone, and telmisartan. Several other drug manufacturers are focused on receiving approval from the FDA for hypertension medicine. For instance, in December 2018, Alembic Pharmaceuticals announced that the company received approval from the US FDA for a new hypertension medicine.

Buy Antihypertensive Drugs Market Report at

Hospital pharmacies are expected to be the most sought-after distribution channel. Additionally, ~44% of the total sales of antihypertensive drugs is expected to take place from hospital pharmacies in 2020. Hospital pharmacies segment is projected to generate a revenue of ~US$ 12.5 Bn in 2020.

Browse More Trending Reports by Transparency Market Research:

Hydrocolloid Dressing Market:

Neonatal and Pediatric Feeding Tubes Market:

Ablation Devices Market:

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453

Back to news